Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication for inclisiran to include patients with high LDL but without a history ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CHICAGO — In adults with atherosclerotic CVD or a risk ...

The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...

Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...

LISBON, Portugal — Using RNA interference to inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) synthesis lowers levels of atherogenic lipoproteins across the board, new results suggest. At ...

WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...